PROstate-specific Membrane Antigen DosImetry- Guided endoradiotherapY: A Randomized- Controlled, Single-blind, Pilot Study of Personalized vs. Fixed-activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
Latest Information Update: 02 May 2025
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Diagnostic use
- Acronyms PRODIGY-2
Most Recent Events
- 02 May 2025 New trial record